A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study - Yazici, Y.; McAlindon, T.E.; Fleischmann, R.; Gibofsky, A.; Lane, N.E.; Kivitz, A.J.; Skrepnik, N.; Armas, E.; Swearingen, C.J.; DiFrancesco, A.; Tambiah, J.R.S.; Hood, J.; et al. (Osteoarthritis and cartilage, 2017)
Keywords: Aged; Antirheumatic Agents - administration & dosage; Antirheumatic Agents - adverse effects; Antirheumatic Agents - pharmacokinetics; Antirheumatic Agents - therapeutic use; DMOAD; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles - administration & dosage; Imidazoles - adverse effects; Imidazoles - pharmacokinetics; Imidazoles - therapeutic use; Indazoles - administration & dosage; Indazoles - adverse effects; Indazoles - pharmacokinetics; Indazoles - therapeutic use; Injections, Intra-Articular; Male; Middle Aged; Osteoarthritis; Osteoarthritis, Knee - diagnostic imaging; Osteoarthritis, Knee - drug therapy; Pain Measurement - methods; Pyridines - administration & dosage; Pyridines - adverse effects; Pyridines - pharmacokinetics; Pyridines - therapeutic use; Radiography; Severity of Illness Index; Small molecule; Wnt pathway; Wnt Signaling Pathway - drug effects; Small molecule; DMOAD; Wnt pathway; Osteoarthritis